List view / Grid view
If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later in the development process. Given that many drugs fail in clinical trials due to nephrotoxicity, this article describes the importance of understanding kidney transporter function in drug development, how current…
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
DNA in the cytoplasm is an indicator of microbial infection, serving as a danger signal and resulting in induction of an innate immune response via the cyclic GAMP synthase (cGAS)/STING (Stimulator of INterferon-sensitive Genes) pathway.
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
Therapeutic monoclonal antibodies are proven and effective treatment options but many of the ‘low-hanging fruit’ therapeutics have already been identified.
In this in-depth focus are features on the best data management options currently available and how the future of drug discovery will be connected and fully automated.
The articles in this in-depth focus explain how informatics aids in the development of genomic research and outline the next steps for AI to progress in pharma.
This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.
Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
Pre-clinical studies demonstrate that inhibiting the ’epichaperome’ can restore neural networks to normal levels. Dr Barbara Wallner at Samus Therapeutics explains how targeting the epichaperome could work as a potential treatment for Alzheimer’s and other neurodegenerative diseases.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
